MARKET

MBRX

MBRX

Moleculin
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.745
-0.035
-0.93%
Opening 12:23 06/16 EDT
OPEN
3.800
PREV CLOSE
3.780
HIGH
3.820
LOW
3.740
VOLUME
85.30K
TURNOVER
--
52 WEEK HIGH
9.30
52 WEEK LOW
3.120
MARKET CAP
106.52M
P/E (TTM)
-2.0836
1D
5D
1M
3M
1Y
5Y
BRIEF-Moleculin Announces Inclusion In The Russell 2000 Index
reuters.com · 1d ago
Moleculin Biotech to join Russell 2000 Index
Moleculin Biotech (MBRX) to be a part of the Russell 2000 Index effective after the close of the U.S. equity markets on June 25, 2021.The Russell 2000 Index measures the performance of the small-cap segment
Seekingalpha · 1d ago
Moleculin Announces Inclusion in the Russell 2000® Index
/PRNewswire/ -- , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that as part of the annual reconstitution of t...
PR Newswire - PRF · 1d ago
BRIEF-Moleculin Biotech Inc Files For Mixed Shelf Of Upto $200 Million
reuters.com · 05/28 22:18
Moleculin Biotech to Start Testing Annamycin in Sarcoma Lung Metastases Patients
Benzinga · 05/25 15:23
BRIEF-Moleculin Commences Phase 1B/2 Clinical Trial Of Annamycin For The Treatment Of Sarcoma Lung Metastases
reuters.com · 05/25 13:30
Moleculin kicks off phase 1b/2 annamycin cancer trial
Moleculin Biotech (MBRX) announces that it has received clearance to initiate its Phase 1b/2 clinical trial evaluating annamycin for the treatment of soft tissue sarcoma ((STS)) lung metastases.The first of several planned clinical
Seekingalpha · 05/25 13:14
Moleculin Biotech Receives Clearance To Initiate Phase 1b/2 Trial Of Annamycin
On May 25, 2021, Moleculin Biotech, Inc. (the “Company”), issued a press release announcing it has received clearance to initiate its Phase 1b/2 clinical trial evaluating Annamycin for the treatment of
Benzinga · 05/25 13:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MBRX. Analyze the recent business situations of Moleculin through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MBRX stock price target is 20.33 with a high estimate of 29.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 49
Institutional Holdings: 2.42M
% Owned: 8.52%
Shares Outstanding: 28.44M
TypeInstitutionsShares
Increased
9
790.53K
New
14
1.14M
Decreased
0
0
Sold Out
12
200.07K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About MBRX
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the treatment of cancers. Its clinical stage drug candidates include Annamycin, WP1066, WP1220, WP1732, WP1122 and WP1234. Annamycin is intended for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. WP1066 is an immune/transcription modulator (p-STAT3 inhibitor) and is intended to target a wide range of tumors, including brain tumors and pancreatic cancer. WP1220 is intended for the topical treatment of cutaneous T-cell lymphoma (CTCL). WP1732 is evaluated for the potential treatment of AML, pancreatic and other cancers. WP1122 and WP1234 are evaluated for the potential to treat brain tumors and pancreatic cancer through its ability to inhibit glycolysis. It is also engaged in development of drug candidates, including additional immune/transcription modulators, as well as metabolism/glycosylation inhibitors.

Webull offers kinds of Moleculin Biotech Inc stock information, including NASDAQ:MBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MBRX stock methods without spending real money on the virtual paper trading platform.